Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Research/Science 8/22/2023
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
View this post in the Community →
Similar Community Posts Join
5 / 349 resultscommunity End of Hair loss ( AGA ) ? Since they produce it in china probably we don’t need to wait other 10 yrs😁
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
community Did UCLA Just Cure Baldness? Check this Out!
UCLA's PP405 shows promise in reactivating dormant hair follicles for hair loss treatment but is still in clinical trials. Minoxidil and finasteride remain common treatments until PP405 becomes available.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Reminder that Kintors Pyrilutamide results will be out this month
Kintor's Pyrilutamide results for hair loss treatment will be released soon. The treatment may replace current treatments like finasteride and minoxidil without systemic side effects.
community Pyrilutamide Phase 3 on its way
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
Related Research
6 / 11 resultsresearch Efficacy and Safety of Topical GT20029 in Male Patients With Androgenetic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
GT20029 helps regrow hair in men with hair loss and is well-tolerated.
research The 100 Most Cited Articles in Androgenetic Alopecia: A Bibliometric Analysis
Recent research on androgenetic alopecia focuses on optimizing treatments, with promising new therapies emerging.
research Updates in Treatment for Androgenetic Alopecia
New treatments for hair loss include low-dose oral minoxidil, light therapy, and innovative therapies targeting hair growth mechanisms.
research What's New in Therapy for Male Androgenetic Alopecia?
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research Androgens and Androgen Receptor in the Management of Skin Diseases
Understanding how androgens and their receptors work can lead to improved treatments for skin diseases.